Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

J. Hiltunen, P. Parmanne, T. Sokka, T. Lamberg, P. Isomäki, O. Kaipiainen-Seppänen, R. Peltomaa, T. Uutela, L. Pirilä, K. Taimen, M. J. Kauppi, T. Yli-Kerttula, R. Tuompo, H. Relas, S. Kortelainen, K. Paalanen, J. Asikainen, P. Ekman, A. Santisteban, K. L. VidqvistK. Tadesse, M. Romu, J. Borodina, P. Elfving, H. Valleala, M. Leirisalo-Repo, V. Rantalaiho, H. Kautiainen, T. S. Jokiranta, K. K. Eklund, for the FinADASpA Study Group

    Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

    30 Lataukset (Pure)

    Abstrakti

    Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Abstract: Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1–2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.

    AlkuperäiskieliEnglanti
    JulkaisuRHEUMATOLOGY INTERNATIONAL
    Vuosikerta42
    Numero6
    Varhainen verkossa julkaisun päivämääräelok. 2021
    DOI - pysyväislinkit
    TilaJulkaistu - 2022
    OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

    Julkaisufoorumi-taso

    • Jufo-taso 1

    !!ASJC Scopus subject areas

    • Immunology and Allergy
    • Rheumatology
    • Immunology

    Sormenjälki

    Sukella tutkimusaiheisiin 'Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

    Siteeraa tätä